STANDARDIZATION OF KI-67 AS A BIOMARKER OF CELL PROLIFERATION
Main Article Content
Authors
A.A. Zhylkibayev
National Center for Biotechnology,13/5 Korgalzhyn road, Astana, 010000, Kazakhstan
N.I. Sarina
National Center for Biotechnology,13/5 Korgalzhyn road, Astana, 010000, Kazakhstan
E.A. Mun
National Center for Biotechnology,13/5 Korgalzhyn road, Astana, 010000, Kazakhstan
S.Z. Eskendirova
National Center for Biotechnology,13/5 Korgalzhyn road, Astana, 010000, Kazakhstan
Abstract
Currently, the most informative, accessible, and common method for evaluating the level of cell proliferative activity is identification and quantification of Ki-67 protein as a universal proliferation biomarker. The Ki-67 antigen is a component of the nuclear matrix, and nuclear core localization changes are observed during the cell cycle. Ki-67 protein is mainly associated with the chromosomes and belongs to the family of perichromonucleic proteins that surround chromosomes during mitosis. Ki-67 is characterized as a large nuclear protein based on cloning and sequencing a cDNA library. It is subjected to conformational changes during the cell cycle. Ki-67 also undergoes post-translational modifications by phosphorylation, accompanied by redistribution from the nucleoplasm into the perichromosomal layer and back during mitosis. Accordingly, Ki-67 is a widely used biomarker for cancer cells, including for pathological diagnosis and monitoring treatment responses. In particular, determination of the expression level of Ki-67 plays an important role in distinguishing the molecular subtypes of breast cancer and is one of the main criteria for determining the appropriate scheme of chemotherapy. However, there is currently no standardization of evaluation methods for predicting the disease outcome and effectiveness of chemotherapy. Researchers have reported the high variability in the Ki-67 index between different laboratories, depending on the choice of primary antibodies, methods for conducting immunohistochemistry, and methods for quantifying expression.
The most appropriate threshold values of Ki-67 expression for clinical monitoring are continuously debated, and determination of a single cut-off point of Ki-67 was shown to not appropriately reflect the heterogeneous biology of the disease. In accordance with the latest recommendations of the St. Gallen conference of 2015, low, medium, and high Ki-67 thresholds were identified to achieve a better response to therapy. Here, we discuss the structure and function of the protein, as well as progress toward achieving a standardized determination method of Ki-67.
Keywords
Ki-67 biomarker, cell proliferation, proliferation activity, breast cancer, protein expression, immunohistochemistry
Article Details
References
Whitfield M., George L., Perou G. Common markers of proliferation. Nature Reviews Cancer, 2006, vol. 6, pp. 99-106. PMID:16491069.
Berridge M. Cell Signalling Biology (Module 9. Cell Cycle and Proliferation). Portland Press Limited. 2014, 652 p. doi: 10.1042/csb0001009.
Gerdes J., Schwab U., Lemke H. et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 1983, vol., no. 31,pp. 13-20. PMID:6339421
Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol., 2000, vol.182, pp.311-322. PMID: 10653597
Sobecki M., Mrouj K., Camasses A.et al. The cell proliferation antigen Ki- 67 organises heterochromatin. eLife , 2016, vol. 7, no.5. 33p. doi: 10.7554/eLife.13722
Sun X., Kaufman P. Ki-67: more than a proliferation marker. Chromosoma . 2018, vol.127, no.2, pp.175-186. doi: 10.1007/s00412-018-0659-8.
Brown D., Gatter K. Ki67 protein: the immaculate deception? Histopathology. 2002. vol.40, no.1., pp.2-11. PMID:11903593
Endl E., Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp. Cell Res., 2000., vol.257, no.2, pp. 231-237. PMID:10837136
Cuylen S., Blaukopf C., Politi A.Z. et al. Ki67 acts as a biological surfactant to disperse mitotic chromosomes . Nature , 2016, vol.535., no. 7611, pp.308-312. doi:10.1038/nature18610
Booth D., Takagi M., Sanchez-Pulido L.. et al. Ki67 is a PP1-interacting protein that organises the mitotic chromosome periphery // eLife, 2014, vol. 27, no.3. 19 p. doi: 10.7554/eLife.01641.
Schlüter C., Duchrow M., Wohlenberg C. et al. The cell proliferation-associated antigen of antibody Ki67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.J.Cell Biol.,1993,vol.123,no.3,pp. 513–522. doi :10.1083/jcb.123.3.513
Atlas of Genetics and Cytogenetics in Oncology and Haematology, URL
Duchrow M., Schlüter C., Wohlenberg C. et al. Molecular characterization of the gene locus of the human cell proliferation associated nuclear protein defined by monoclonal antibody Ki67. Cell Prolif., 1996, vol. 29, no.1, pp.1–12. PMID:8603106
Ross W., Hall P. Ki67: from antibody to molecule to understanding . J.Clin. Pathol. ,1995,vol. 48, no.3, pp. 113-117. doi: 10.1136/mp.48.3.m113
Gerdes J., Li L., Schlueter C. et al. Immunobiochemical and molecular biologic characterization of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki67 . Am. J. Pathol., 1991, vol. 138, no.4, pp. 867–873. PMID: 2012175
Takagi M., Matsuoka Y., Kurihara T. Chmadrin: a novel Ki67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure . J. Cell Sci., 1999, vol. 112,no.15, pp. 2463–2472. PMID: 10393802
McCallum D., Hall P.A. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding . Exp Cell Res.,1999, vol. 252, no. 1, pp. 186–198. doi:10.1006/excr.1999.4600
Endl E., Gerdes J. Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. J. Cell Physiol., 2000, vol.182, no.3, pp. 371-380. PMID:10653604
Sсholzen T., Endi E., Wohlenberg C. et al. The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1 ) family: a potential role in the regulation of high-order chromatin structure . J. Pathol. , 2002, vol.196 , no.2, pp. 135-144. doi:10.1002/path.1016
Yerushalmi R., Woods R., Ravdin P. et al. Ki67 in breast cancer: prognostic and predictive potential . The lancet oncology. , 2010, vol. 11, no.2, pp. 174-183. doi: 10.1016/S1470-2045(09)70262-1
Mannell A. The role of Ki-67 in breast cancer S. Afr. J. Surg., 2016, vol.54, no.2, pp.10-13. PMID:28240498
Ragab H., Samy N., Afify M. et al. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J. Genetic Engineering and Biotechnology. 2018, vol. 16, no.2, pp. 479–484. doi: 10.1016/j.jgeb.2018.03.002
Kheirandish S, Homaee F. Ki67- protein: a proliferation index in breast cancer. Rev Clin Med., 2015, vol.2,no.4,pp. 205-208. doi: 10.17463/RCM.2015.04.010
Stuart-Harris R., Caldas C., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients . Breast , 2008, vol.17, no.4, pp.323-334. doi: 10.1016/j.breast.2008.02.002
De Azambuja E., Cardoso F., de Castro G. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Brit. J. Cancer, 2007, vol. 96,no.10 , pp.1504-1513. doi:10.1038/sj.bjc.6603756
Li F.Y., Wu S.G., Zhou J. et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. Plos One, 2014, vol. 9, no.2, e87264. doi:10.1371/journal.pone.0087264
Luporsi E., Andre F., Spyratos F. et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat., 2012, vol.132, no. 3, pp. 895-915. doi: 10.1007/s10549-011-1837-z
Goldhirsch A., Ingle J.N., Gelber R.D. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann. Oncol., 2009, vol.20, no. 8, pp.1319-1329. doi: 10.1093/annonc/mdp322
Dowsett M., Nielsen T., A'Hern R. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl. Cancer Inst., 2011, vol.103,no.22 , pp.1656-64. doi: 10.1093/jnci/djr393.
Kubbutat M., Key G., Duchrow M. et al. Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein). J. Clin Pathol ., 1994, vol.47, no.6,pp. 524-528. doi: 10.1136/jcp.47.6.524
Cattoretti G., Becker M., Key G. et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB- 1 and MIB- 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. Journal of Pathology, 1992,vol. 168. no.4, pp. 357-363 doi: 10.1002/path.1711680404
Key G, Becker MHG, Baron B, et al. New Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 66 bp repetitive elements encoding for the Ki-67 epitope. Lab Invest, 1993, vol.68,no.6, pp.629-636. PMID: 7685843
Lindboe C., Torp S. Comparison of Ki-67 equivalent antibodies . .J. Clin. Pathol., 2002, vol.55, no.6, pp.467–471. doi: 10.1136/jcp.55.6.467
Zabaglo L, Salter J, Anderson H, et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol., 2010, vol.63,no.9, pp.800–804. doi : 10.1136/jcp.2010.07757
Viale G., Newel A., Walker E. et al. Ki-67 (30-9) scoring and differentiation in luminal A and luminal B breast cancer subtypes. Cancer Res., 2019, vol.79 (4 Suppl. Abstract PD2-11 ). doi:10.1158/1538-7445.SABCS18-PD2-11
Acs B., Kulka J., Kovacs A. et al. Comparison of five Ki67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: Does the antibody matter?. Human Pathology, 2017, vol.65, pp.31-40, doi: 10.1016/j.humpath.2017.01.011
Nordic Immunohistochemical Quality Control (Ki67), 2016, assessments run B22. Available at: URL (Accessed 12 July 2016).
Dodson A. Standardisation of Ki67 in breast cancer prognostication . 3rdNordiQC Conference on Applied Immunohistochemistry. 2017. Denmark. Available at: URL (Accessed 8 June 2017)
Polley M., Leung S., McShane L. et al. An International Ki67 Reproducibility Study. J. Natl. Cancer Inst., 2013,vol.105, no.24, pp.1897–1906. doi:10.1093/jnci/djt306
Polley M., Leung S., Gao D. et al. An international study to increase concordance in Ki67 scoring. Modern Pathology , 2015, vol.28, no.6, pp.778–786. doi: 10.1038/modpathol.2015.38
Leung S., Nielsen T., Zabaglo L. et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Breast Cancer, 2016, vol.18, no.2, 16014; doi:10.1038/npjbcancer.2016.14
Penault-Llorca F., Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology, 2017, vol.49, no.2, pp. 166–171. doi: Crossref
Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care (Basel), 2015, vol.10,no.2, pp.124-130. doi.org/10.1159/000430488
Tashima R, Nishimura R, Osako T. et al. Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: a retrospective study. PLoS One, 2015, vol.10, no.7, e0119565. doi.org/10.1371/journal.pone.0119565
Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat.,2015, vol.153,no.3, pp. 477-491. doi.org/10.1007/s10549-015-3559-0
Bustreo S, Osella-Abate S, Cassoni P. et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat.,2016, vol.157, no.2,pp.363-371 doi.org/10.1007/s10549-016-3817-9
Denkert C, Loibl S, Muller B. et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol., 2013, vol.24, no.11, pp. 2786-2793. doi: 10.1093/annonc/mdt350
Koopman T., Buikema H., Hollema G.et al. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter platform agreement. Breast Cancer Res. and Treat., 2018, vol.169, pp. 33–42. doi.org/10.1007/s10549-018-4669-2